Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antivirals.
Journal
Journal of medical virology
Journal Volume
96
Journal Issue
5
Pages
e29675
ISSN
1096-9071
Date Issued
2024-05
Author(s)
Chang, Yu-Ping
Lee, Ji-Yuh
Chen, Chi-Yi
Kao, Wei-Yu
Lin, Chih-Lin
Yang, Sheng-Shun
Shih, Yu-Lueng
Peng, Cheng-Yuan
Lee, Fu-Jen
Tsai, Ming-Chang
Abstract
Early confirmation of sustained virologic response (SVR) or viral relapse after direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection is essential based on public health perspectives, particularly for patients with high risk of nonadherence to posttreatment follow-ups. A total of 1011 patients who achieved end-of-treatment virologic response, including 526 receiving fixed-dose pangenotypic DAAs, and 485 receiving other types of DAAs, who had available off-treatment weeks 4 and 12 serum HCV RNA data to confirm SVR at off-treatment week 12 (SVR) or viral relapse were included. The positive predictive value (PPV) and negative predictive value (NPV) of SVR to predict patients with SVR or viral relapse were reported. Furthermore, we analyzed the proportion of concordance between SVR and SVR in 943 patients with available SVR data. The PPV and NPV of SVR to predict SVR were 98.5% (95% confidence interval [CI]: 98.0-98.9) and 100% (95% CI: 66.4-100) in the entire population. The PPV of SVR to predict SVR in patients receiving fixed-dose pangenotypic DAAs was higher than those receiving other types of DAAs (99.8% [95% CI: 98.9-100] vs. 97.1% [95% CI: 96.2-97.8], p < 0.001). The NPVs of SVR to predict viral relapse were 100%, regardless of the type of DAAs. Moreover, the concordance between SVR and SVR was 100%. In conclusion, an off-treatment week 4 serum HCV RNA testing is sufficient to provide an excellent prediction power of SVR or viral relapse at off-treatment week 12 among patients with HCV who are treated with fixed-dose pangenotypic DAAs.
Subjects
direct‐acting antiviral
hepatitis C virus
pangenotypic
sustained virologic response
SDGs
Type
journal article